Exercise-induced myokines and their effect on prostate cancer.
Adenocarcinoma
/ metabolism
Apoptosis
/ physiology
Cell Cycle Checkpoints
/ physiology
Cell Proliferation
/ physiology
Cytokines
/ metabolism
Decorin
/ metabolism
Epithelial-Mesenchymal Transition
/ physiology
Exercise
/ physiology
Fibronectins
/ metabolism
Humans
Hyperinsulinism
/ metabolism
Hyperlipidemias
/ metabolism
Insulin Resistance
/ physiology
Interleukin-10
/ metabolism
Interleukin-15
/ metabolism
Interleukin-6
/ metabolism
Male
Muscle, Skeletal
/ metabolism
Myostatin
/ metabolism
Obesity
/ metabolism
Oncostatin M
/ metabolism
Osteonectin
/ metabolism
Prostatic Neoplasms
/ metabolism
Journal
Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
accepted:
04
05
2021
pubmed:
24
6
2021
medline:
29
1
2022
entrez:
23
6
2021
Statut:
ppublish
Résumé
Exercise is recognized by clinicians in the field of clinical oncology for its potential role in reducing the risk of certain cancers and in reducing the risk of disease recurrence and progression; yet, the underlying mechanisms behind this reduction in risk are not fully understood. Studies applying post-exercise blood serum directly to various types of cancer cell lines provide insight that exercise might have a role in inhibiting cancer growth via altered soluble and cell-free blood contents. Myokines, which are cytokines produced by muscle and secreted into the bloodstream, might offer multiple benefits to cellular metabolism (such as a reduction in insulin resistance, improved glucose uptake and reduced adiposity), and blood myokine levels can be altered with exercise. Alterations in the levels of myokines such as IL-6, IL-15, IL-10, irisin, secreted protein acidic risk in cysteine (SPARC), myostatin, oncostatin M and decorin might exert a direct inhibitory effect on cancer growth via inhibiting proliferation, promoting apoptosis, inducing cell-cycle arrest and inhibiting the epithermal transition to mesenchymal cells. The association of insulin resistance, hyperinsulinaemia and hyperlipidaemia with obesity can create a tumour-favourable environment; exercise-induced myokines can manipulate this environment by regulating adipose tissue and adipocytes. Exercise-induced myokines also have a critical role in increasing cytotoxicity and the infiltration of immune cells into the tumour.
Identifiants
pubmed: 34158658
doi: 10.1038/s41585-021-00476-y
pii: 10.1038/s41585-021-00476-y
doi:
Substances chimiques
Cytokines
0
Decorin
0
FNDC5 protein, human
0
Fibronectins
0
Interleukin-15
0
Interleukin-6
0
Myostatin
0
Osteonectin
0
Oncostatin M
106956-32-5
Interleukin-10
130068-27-8
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
519-542Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. Springer Nature Limited.
Références
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
pubmed: 30207593
doi: 10.3322/caac.21492
Anand, P. et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. 25, 2097–2116 (2008).
pubmed: 18626751
pmcid: 2515569
doi: 10.1007/s11095-008-9661-9
Bourke, L. et al. Exercise for men with prostate cancer: a systematic review and meta-analysis. Eur. Urol. 69, 693–703 (2016).
pubmed: 26632144
doi: 10.1016/j.eururo.2015.10.047
Gunnell, A. S. et al. Physical activity and survival among long-term cancer survivor and non-cancer cohorts. Front. Public Health 5, 19 (2017).
pubmed: 28261579
pmcid: 5306330
doi: 10.3389/fpubh.2017.00019
Nieto-Vazquez, I., Fernandez-Veledo, S., de Alvaro, C. & Lorenzo, M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 57, 3211–3221 (2008).
pubmed: 18796617
pmcid: 2584126
doi: 10.2337/db07-1062
Shephard, R. J. Physical activity and prostate cancer: an updated review. Sports Med. 47, 1055–1073 (2017).
pubmed: 27844337
doi: 10.1007/s40279-016-0648-0
Kenfield, S. A., Stampfer, M. J., Giovannucci, E. & Chan, J. M. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J. Clin. Oncol. 29, 726–732 (2011).
pubmed: 21205749
pmcid: 3056656
doi: 10.1200/JCO.2010.31.5226
Datta, D., Aftabuddin, M., Gupta, D. K., Raha, S. & Sen, P. Human prostate cancer hallmarks map. Sci. Rep. 6, 30691 (2016).
pubmed: 27476486
pmcid: 4967902
doi: 10.1038/srep30691
Potosky, A. L., Miller, B. A., Albertsen, P. C. & Kramer, B. S. The role of increasing detection in the rising incidence of prostate cancer. JAMA 273, 548–552 (1995).
pubmed: 7530782
doi: 10.1001/jama.1995.03520310046028
Allott, E. H., Masko, E. M. & Freedland, S. J. Obesity and prostate cancer: weighing the evidence. Eur. Urol. 63, 800–809 (2013).
pubmed: 23219374
doi: 10.1016/j.eururo.2012.11.013
Jones, L. W. & Alfano, C. M. Exercise-oncology research: past, present, and future. Acta. Oncol. 52, 195–215 (2013).
pubmed: 23244677
doi: 10.3109/0284186X.2012.742564
Christensen, J. F., Simonsen, C. & Hojman, P. Exercise training in cancer control and treatment. Compr. Physiol. 9, 165–205 (2018).
pubmed: 30549018
doi: 10.1002/cphy.c180016
Fiuza-Luces, C., Garatachea, N., Berger, N. A. & Lucia, A. Exercise is the real polypill. Physiology 28, 330–358 (2013).
pubmed: 23997192
doi: 10.1152/physiol.00019.2013
Chang, S. et al. Leptin and prostate cancer. Prostate 46, 62–67 (2001).
pubmed: 11170133
doi: 10.1002/1097-0045(200101)46:1<62::AID-PROS1009>3.0.CO;2-V
Dethlefsen, C. et al. Exercise-induced catecholamines activate the hippo tumor suppressor pathway to reduce risks of breast cancer development. Cancer Res. 77, 4894–4904 (2017).
pubmed: 28887324
doi: 10.1158/0008-5472.CAN-16-3125
Dethlefsen, C. et al. Exercise regulates breast cancer cell viability: systemic training adaptations versus acute exercise responses. Breast Cancer Res. Treat. 159, 469–479 (2016).
pubmed: 27601139
doi: 10.1007/s10549-016-3970-1
Dethlefsen, C., Pedersen, K. S. & Hojman, P. Every exercise bout matters: linking systemic exercise responses to breast cancer control. Breast Cancer Res. Treat. 162, 399–408 (2017).
pubmed: 28138894
doi: 10.1007/s10549-017-4129-4
Devin, J. L. et al. Acute high intensity interval exercise reduces colon cancer cell growth. J. Physiol. 597, 2177–2184 (2019).
pubmed: 30812059
pmcid: 6462486
doi: 10.1113/JP277648
Kurgan, N. et al. Inhibition of human lung cancer cell proliferation and survival by post-exercise serum is associated with the inhibition of Akt, mTOR, p70 S6K, and Erk1/2. Cancers 9, 46 (2017).
pmcid: 5447956
doi: 10.3390/cancers9050046
Rundqvist, H. et al. Effect of acute exercise on prostate cancer cell growth. PLoS ONE 8, e67579 (2013).
pubmed: 23861774
pmcid: 3702495
doi: 10.1371/journal.pone.0067579
Pedersen, B. K. & Febbraio, M. A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 8, 457–465 (2012).
pubmed: 22473333
doi: 10.1038/nrendo.2012.49
Aoi, W. et al. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut 62, 882–889 (2013).
pubmed: 22851666
doi: 10.1136/gutjnl-2011-300776
Hojman, P. et al. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. Am. J. Physiol. Endocrinol. Metab. 301, E504–E510 (2011).
pubmed: 21653222
doi: 10.1152/ajpendo.00520.2010
Pedersen, B. K. The physiology of optimizing health with a focus on exercise as medicine. Annu. Rev. Physiol. 81, 607–627 (2019).
pubmed: 30526319
doi: 10.1146/annurev-physiol-020518-114339
Richman, E. L. et al. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 71, 3889–3895 (2011).
pubmed: 21610110
pmcid: 3107352
doi: 10.1158/0008-5472.CAN-10-3932
Hayes, S. C., Newton, R. U., Spence, R. R. & Galvão, D. A. The exercise and sports science Australia position statement: exercise medicine in cancer management. J. Sci. Med. Sport 22, 1175–1199 (2019).
pubmed: 31277921
doi: 10.1016/j.jsams.2019.05.003
Jones, L. W. Precision oncology framework for investigation of exercise as treatment for cancer. J. Clin. Oncol. 33, 4134–4137 (2015).
pubmed: 26460301
pmcid: 4979240
doi: 10.1200/JCO.2015.62.7687
Sasso, J. P. et al. A framework for prescription in exercise-oncology research. J. Cachexia Sarcopenia Muscle 6, 115–124 (2015).
pubmed: 26136187
pmcid: 4458077
doi: 10.1002/jcsm.12042
Courneya, K. S. et al. Effects of supervised exercise on progression-free survival in lymphoma patients: an exploratory follow-up of the HELP Trial. Cancer Causes Control. 26, 269–276 (2015).
pubmed: 25491935
doi: 10.1007/s10552-014-0508-x
Courneya, K. S. et al. Effects of exercise during adjuvant chemotherapy on breast cancer outcomes. Med. Sci. Sports Exerc. 46, 1744–1751 (2014).
pubmed: 24633595
doi: 10.1249/MSS.0000000000000297
Hayes, S. C. et al. Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials. Breast Cancer Res. Treat. 167, 505–514 (2018).
pubmed: 29063309
doi: 10.1007/s10549-017-4541-9
Rief, H. et al. Resistance training concomitant to radiotherapy of spinal bone metastases - survival and prognostic factors of a randomized trial. Radiat. Oncol. 11, 97 (2016).
pubmed: 27464793
pmcid: 4963927
doi: 10.1186/s13014-016-0675-x
Galvao, D. A. et al. Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nat. Rev. Urol. 13, 258–265 (2016).
pubmed: 26954333
doi: 10.1038/nrurol.2016.46
Keilani, M. et al. Effects of resistance exercise in prostate cancer patients: a meta-analysis. Support. Care Cancer 25, 2953–2968 (2017).
pubmed: 28600706
pmcid: 5527087
doi: 10.1007/s00520-017-3771-z
Pak, S. et al. Association of body composition with survival and treatment efficacy in castration-resistant prostate cancer. Front. Oncol. 10, 558 (2020).
pubmed: 32363164
pmcid: 7180747
doi: 10.3389/fonc.2020.00558
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D. & Newton, R. U. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J. Clin. Oncol. 28, 340–347 (2010).
pubmed: 19949016
doi: 10.1200/JCO.2009.23.2488
Lopez, P., Taaffe, D. R., Newton, R. U. & Galvao, D. A. Resistance exercise dosage in men with prostate cancer: Systematic review, meta-analysis, and meta-regression. Med. Sci. Sports Exerc. 53, 459–469 (2020).
pmcid: 7886340
doi: 10.1249/MSS.0000000000002503
Betof, A. S. et al. Modulation of murine breast tumor vascularity, hypoxia, and chemotherapeutic response by exercise. J. Natl Cancer Inst. 107, djv040 (2015).
pubmed: 25780062
pmcid: 4822524
doi: 10.1093/jnci/djv040
Jones, L. W. Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts. Clin. Cancer Res. 11, 6695–6698 (2005).
pubmed: 16166449
doi: 10.1158/1078-0432.CCR-05-0844
McCullough, D. J., Stabley, J. N., Siemann, D. W. & Behnke, B. J. Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. J. Natl Cancer Inst. 106, dju036 (2014).
pubmed: 24627275
pmcid: 3982888
doi: 10.1093/jnci/dju036
Schadler, K. L. et al. Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy. Oncotarget 7, 65429–65440 (2016).
pubmed: 27589843
pmcid: 5323166
doi: 10.18632/oncotarget.11748
Schumacher, O. et al. Exercise modulation of tumour perfusion and hypoxia to improve radiotherapy response in prostate cancer. Prostate Cancer Prostatic Dis. 24, 1–14 (2021).
pubmed: 32632128
doi: 10.1038/s41391-020-0245-z
Muz, B., de la Puente, P., Azab, F. & Azab, A. K. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 3, 83–92 (2015).
pubmed: 27774485
pmcid: 5045092
doi: 10.2147/HP.S93413
Barnard, R. J., Ngo, T. H., Leung, P. S., Aronson, W. J. & Golding, L. A. A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate 56, 201–206 (2003).
pubmed: 12772189
doi: 10.1002/pros.10251
Leung, P. S., Aronson, W. J., Ngo, T. H., Golding, L. A. & Barnard, R. J. Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. J. Appl. Physiol. 96, 450–454 (2004).
pubmed: 14715676
doi: 10.1152/japplphysiol.00871.2003
Ngo, T. H., Barnard, R. J., Leung, P. S., Cohen, P. & Aronson, W. J. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144, 2319–2324 (2003).
pubmed: 12746292
doi: 10.1210/en.2003-221028
Yu, M. et al. Exercise activates p53 and negatively regulates IGF-1 pathway in epidermis within a skin cancer model. PLoS ONE 11, e0160939 (2016).
pubmed: 27509024
pmcid: 4979999
doi: 10.1371/journal.pone.0160939
Galvao, D. A. et al. Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis. 11, 160–165 (2008).
pubmed: 17637762
doi: 10.1038/sj.pcan.4500991
Ilagan, E. & Manning, B. D. Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer 2, 241–251 (2016).
pubmed: 27668290
pmcid: 5033243
doi: 10.1016/j.trecan.2016.03.008
Sarker, D., Reid, A. H., Yap, T. A. & de Bono, J. S. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer. Res. 15, 4799–4805 (2009).
pubmed: 19638457
doi: 10.1158/1078-0432.CCR-08-0125
Abylkassov, R. & Xie, Y. Role of Yes-associated protein in cancer: an update. Oncol. Lett. 12, 2277–2282 (2016).
pubmed: 27698789
pmcid: 5038596
doi: 10.3892/ol.2016.4955
Nørgaard-Christensen, N. PO-103 Regulation of prostate cancer cell growth and signalling by exercise. [abstract PO-103]. ESMO Open 3, A61–A61 (2018).
doi: 10.1136/esmoopen-2018-EACR25.144
Cohen, D. H. & LeRoith, D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr. Relat. Cancer 19, F27–F45 (2012).
pubmed: 22593429
doi: 10.1530/ERC-11-0374
Pedersen, B. K. et al. Searching for the exercise factor: is IL-6 a candidate? J. Muscle Res. Cell Motil. 24, 113–119 (2003).
pubmed: 14609022
doi: 10.1023/A:1026070911202
Pedersen, B. K., Akerstrom, T. C., Nielsen, A. R. & Fischer, C. P. Role of myokines in exercise and metabolism. J. Appl. Physiol. 103, 1093–1098 (2007).
pubmed: 17347387
doi: 10.1152/japplphysiol.00080.2007
Ruiz-Casado, A. et al. Exercise and the hallmarks of cancer. Trends Cancer 3, 423–441 (2017).
pubmed: 28718417
doi: 10.1016/j.trecan.2017.04.007
Grant, S. L. & Begley, C. G. The oncostatin M signalling pathway: reversing the neoplastic phenotype? Mol. Med. Today 5, 406–412 (1999).
pubmed: 10462753
doi: 10.1016/S1357-4310(99)01540-3
Hutt, J. A. & DeWille, J. W. Oncostatin M induces growth arrest of mammary epithelium via a CCAAT/enhancer-binding protein delta-dependent pathway. Mol. Cancer Ther. 1, 601–610 (2002).
pubmed: 12479220
Liu, J. et al. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene. Cell Growth Differ. 8, 667–676 (1997).
pubmed: 9186000
Hermanns, H. M. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor. Rev. 26, 545–558 (2015).
pubmed: 26198770
doi: 10.1016/j.cytogfr.2015.07.006
Masjedi, A. et al. Oncostatin M: a mysterious cytokine in cancers. Int. Immunopharmacol. 90, 107158 (2021).
pubmed: 33187910
doi: 10.1016/j.intimp.2020.107158
Mori, S., Murakami-Mori, K. & Bonavida, B. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. Anticancer. Res. 19, 1011–1015 (1999).
pubmed: 10368647
Lee, M. J. et al. Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and TGFBI. Int. J. Biochem. Cell Biol. 45, 1869–1877 (2013).
pubmed: 23735324
doi: 10.1016/j.biocel.2013.05.027
Sterbova, S., Karlsson, T. & Persson, E. Oncostatin M induces tumorigenic properties in non-transformed human prostate epithelial cells, in part through activation of signal transducer and activator of transcription 3 (STAT3). Biochem. Biophys. Res. Commun. 498, 769–774 (2018).
pubmed: 29526757
doi: 10.1016/j.bbrc.2018.03.056
Catoire, M., Mensink, M., Kalkhoven, E., Schrauwen, P. & Kersten, S. Identification of human exercise-induced myokines using secretome analysis. Physiol. Genomics 46, 256–267 (2014).
pubmed: 24520153
doi: 10.1152/physiolgenomics.00174.2013
Nie, J. & Sage, E. H. SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling. J. Biol. Chem. 284, 1279–1290 (2009).
pubmed: 18990699
pmcid: 2613608
doi: 10.1074/jbc.M808285200
Brekken, R. A. & Sage, E. H. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 19, 816–827 (2001).
pubmed: 11223341
doi: 10.1016/S0945-053X(00)00133-5
Puolakkainen, P. A., Brekken, R. A., Muneer, S. & Sage, E. H. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol. Cancer Res. 2, 215–224 (2004).
pubmed: 15140943
doi: 10.1158/1541-7786.215.2.4
Said, N. et al. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene 28, 3487–3498 (2009).
pubmed: 19597474
doi: 10.1038/onc.2009.205
Tai, I. T. & Tang, M. J. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist. Updat. 11, 231–246 (2008).
pubmed: 18849185
doi: 10.1016/j.drup.2008.08.005
Yiu, G. K. et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol. 159, 609–622 (2001).
pubmed: 11485919
pmcid: 1850537
doi: 10.1016/S0002-9440(10)61732-4
Said, N. & Motamed, K. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am. J. Pathol. 167, 1739–1752 (2005).
pubmed: 16314484
pmcid: 1613196
doi: 10.1016/S0002-9440(10)61255-2
Shin, M. et al. Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1. Prostate 73, 1159–1170 (2013).
pubmed: 23532895
doi: 10.1002/pros.22664
Kapinas, K. et al. Bone matrix osteonectin limits prostate cancer cell growth and survival. Matrix Biol. 31, 299–307 (2012).
pubmed: 22525512
pmcid: 3367100
doi: 10.1016/j.matbio.2012.03.002
Thomas, R., True, L. D., Bassuk, J. A., Lange, P. H. & Vessella, R. L. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin. Cancer Res. 6, 1140–1149 (2000).
pubmed: 10741745
Jeldres, C., Johnston, R. B., Porter, C. R. & Nelson, P. Association of SPARC expression with metastatic progression and prostate cancer-specific mortality after radical prostatectomy. J. Clin. Oncol. 31, 5071–5071 (2013).
doi: 10.1200/jco.2013.31.15_suppl.5071
Bostrom, P. et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463–468 (2012).
pubmed: 22237023
pmcid: 3522098
doi: 10.1038/nature10777
Huh, J. Y. et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61, 1725–1738 (2012).
pubmed: 23018146
pmcid: 3614417
doi: 10.1016/j.metabol.2012.09.002
Novelle, M. G., Contreras, C., Romero-Pico, A., Lopez, M. & Dieguez, C. Irisin, two years later. Int. J. Endocrinol. 2013, 746281 (2013).
pubmed: 24298283
pmcid: 3835481
doi: 10.1155/2013/746281
Gannon, N. P., Vaughan, R. A., Garcia-Smith, R., Bisoffi, M. & Trujillo, K. A. Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. Int. J. Cancer 136, E197–E202 (2015).
pubmed: 25124080
doi: 10.1002/ijc.29142
Liu, J., Song, N., Huang, Y. & Chen, Y. Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway. Sci. Rep. 8, 15247 (2018).
pubmed: 30323244
pmcid: 6189061
doi: 10.1038/s41598-018-33229-w
Shao, L. et al. Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. Biochem. Biophys. Res. Commun. 485, 598–605 (2017).
pubmed: 27986567
doi: 10.1016/j.bbrc.2016.12.084
Tekin, S., Erden, Y., Sandal, S. & Yilmaz, B. Is irisin an anticarcinogenic peptide? Med. Sci. 4, 2172–2180 (2015).
doi: 10.5455/medscience.2014.03.8210
Wang, Y. et al. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int. J. Oncol. 50, 606–612 (2017).
pubmed: 28000865
doi: 10.3892/ijo.2016.3804
Brenmoehl, J. et al. Irisin is elevated in skeletal muscle and serum of mice immediately after acute exercise. Int. J. Biol. Sci. 10, 338–349 (2014).
pubmed: 24644429
pmcid: 3957089
doi: 10.7150/ijbs.7972
Kim, H. J., So, B., Choi, M., Kang, D. & Song, W. Resistance exercise training increases the expression of irisin concomitant with improvement of muscle function in aging mice and humans. Exp. Gerontol. 70, 11–17 (2015).
pubmed: 26183690
doi: 10.1016/j.exger.2015.07.006
Lu, Y. et al. Swimming exercise increases serum irisin level and reduces body fat mass in high-fat-diet fed Wistar rats. Lipids Health Dis. 15, 93 (2016).
pubmed: 27177924
pmcid: 4866429
doi: 10.1186/s12944-016-0263-y
Miyamoto-Mikami, E. et al. Endurance training-induced increase in circulating irisin levels is associated with reduction of abdominal visceral fat in middle-aged and older adults. PLoS ONE 10, e0120354 (2015).
pubmed: 25793753
pmcid: 4368602
doi: 10.1371/journal.pone.0120354
Norheim, F. et al. The effects of acute and chronic exercise on PGC-1alpha, irisin and browning of subcutaneous adipose tissue in humans. FEBS J. 281, 739–749 (2014).
pubmed: 24237962
doi: 10.1111/febs.12619
Tsuchiya, Y. et al. High-intensity exercise causes greater irisin response compared with low-intensity exercise under similar energy consumption. Tohoku J. Exp. Med. 233, 135–140 (2014).
pubmed: 24910199
doi: 10.1620/tjem.233.135
Yang, X. Q. et al. Swimming intervention mitigates HFD-induced obesity of rats through PGC-1alpha-irisin pathway. Eur. Rev. Med. Pharmacol. Sci. 20, 2123–2130 (2016).
pubmed: 27249613
Sofeu Feugaing, D. D., Gotte, M. & Viola, M. More than matrix: the multifaceted role of decorin in cancer. Eur. J. Cell Biol. 92, 1–11 (2013).
pubmed: 23058688
doi: 10.1016/j.ejcb.2012.08.004
Bozoky, B. et al. Decreased decorin expression in the tumor microenvironment. Cancer Med. 3, 485–491 (2014).
pubmed: 24634138
pmcid: 4101739
doi: 10.1002/cam4.231
Hu, Y. et al. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11, 1042–1053 (2009).
pubmed: 19794963
pmcid: 2745670
doi: 10.1593/neo.09760
Santra, M., Eichstetter, I. & Iozzo, R. V. An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J. Biol. Chem. 275, 35153–35161 (2000).
pubmed: 10942781
doi: 10.1074/jbc.M006821200
Seidler, D. G. et al. Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J. Biol. Chem. 281, 26408–26418 (2006).
pubmed: 16835231
doi: 10.1074/jbc.M602853200
Shi, X., Liang, W., Yang, W., Xia, R. & Song, Y. Decorin is responsible for progression of non-small-cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol. 36, 3345–3354 (2015).
pubmed: 25524578
doi: 10.1007/s13277-014-2968-8
Xu, W. et al. The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther. 22, 247–256 (2015).
pubmed: 25503693
doi: 10.1038/gt.2014.110
Heinemeier, K. M., Bjerrum, S. S., Schjerling, P. & Kjaer, M. Expression of extracellular matrix components and related growth factors in human tendon and muscle after acute exercise. Scand. J. Med. Sci. Sports 23, e150–e161 (2013).
pubmed: 22107086
doi: 10.1111/j.1600-0838.2011.01414.x
Kanzleiter, T. et al. The myokine decorin is regulated by contraction and involved in muscle hypertrophy. Biochem. Biophys. Res. Commun. 450, 1089–1094 (2014).
pubmed: 24996176
doi: 10.1016/j.bbrc.2014.06.123
Di Lorenzo, G. et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 8, 3438–3444 (2002).
pubmed: 12429632
Pignon, J. C. et al. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Res. 69, 2941–2949 (2009).
pubmed: 19318561
doi: 10.1158/0008-5472.CAN-08-3760
Chung, T. D., Yu, J. J., Spiotto, M. T., Bartkowski, M. & Simons, J. W. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38, 199–207 (1999).
pubmed: 10068344
doi: 10.1002/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H
Hobisch, A. et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 58, 4640–4645 (1998).
pubmed: 9788616
Jia, L. et al. Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res. 64, 2619–2626 (2004).
pubmed: 15059919
doi: 10.1158/0008-5472.CAN-03-3486
Lee, S. O., Chun, J. Y., Nadiminty, N., Lou, W. & Gao, A. C. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 67, 764–773 (2007).
pubmed: 17373716
doi: 10.1002/pros.20553
Lin, D. L., Whitney, M. C., Yao, Z. & Keller, E. T. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin. Cancer Res. 7, 1773–1781 (2001).
pubmed: 11410519
Spiotto, M. T. & Chung, T. D. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 42, 186–195 (2000).
pubmed: 10639189
doi: 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E
Wallner, L. et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res. 66, 3087–3095 (2006).
pubmed: 16540658
doi: 10.1158/0008-5472.CAN-05-3447
Farmawati, A. et al. Characterization of contraction-induced IL-6 up-regulation using contractile C2C12 myotubes. Endocr. J. 60, 137–147 (2013).
pubmed: 23037942
doi: 10.1507/endocrj.EJ12-0316
Febbraio, M. A. et al. Hepatosplanchnic clearance of interleukin-6 in humans during exercise. Am. J. Physiol. Endocrinol. Metab. 285, E397–E402 (2003).
pubmed: 12857677
doi: 10.1152/ajpendo.00134.2003
Hiscock, N., Chan, M. H., Bisucci, T., Darby, I. A. & Febbraio, M. A. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J. 18, 992–994 (2004).
pubmed: 15059966
doi: 10.1096/fj.03-1259fje
Jonsdottir, I. H. et al. Muscle contractions induce interleukin-6 mRNA production in rat skeletal muscles. J. Physiol. 528, 157–163 (2000).
pubmed: 11018114
pmcid: 2270126
doi: 10.1111/j.1469-7793.2000.00157.x
Keller, C. et al. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J. 15, 2748–2750 (2001).
pubmed: 11687509
doi: 10.1096/fj.01-0507fje
Ostrowski, K., Schjerling, P. & Pedersen, B. K. Physical activity and plasma interleukin-6 in humans — effect of intensity of exercise. Eur. J. Appl. Physiol. 83, 512–515 (2000).
pubmed: 11192058
doi: 10.1007/s004210000312
Steensberg, A. et al. IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 283, E1272–E1278 (2002).
pubmed: 12388119
doi: 10.1152/ajpendo.00255.2002
Bruun, J. M., Helge, J. W., Richelsen, B. & Stallknecht, B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am. J. Physiol. Endocrinol. Metab. 290, E961–E967 (2006).
pubmed: 16352667
doi: 10.1152/ajpendo.00506.2005
Goldhammer, E. et al. Exercise training modulates cytokines activity in coronary heart disease patients. Int. J. Cardiol. 100, 93–99 (2005).
pubmed: 15820291
doi: 10.1016/j.ijcard.2004.08.073
Kohut, M. L. et al. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav. Immun. 20, 201–209 (2006).
pubmed: 16504463
doi: 10.1016/j.bbi.2005.12.002
Adachi, M. et al. Androgen-insensitivity syndrome as a possible coactivator disease. N. Engl. J. Med. 343, 856–862 (2000).
pubmed: 10995865
doi: 10.1056/NEJM200009213431205
Iyengar, N. M., Hudis, C. A. & Dannenberg, A. J. Obesity and cancer: local and systemic mechanisms. Annu. Rev. Med. 66, 297–309 (2015).
pubmed: 25587653
doi: 10.1146/annurev-med-050913-022228
Cox, M. E. et al. Insulin receptor expression by human prostate cancers. Prostate 69, 33–40 (2009).
pubmed: 18785179
doi: 10.1002/pros.20852
Venkateswaran, V. et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J. Natl Cancer Inst. 99, 1793–1800 (2007).
pubmed: 18042933
doi: 10.1093/jnci/djm231
Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 12, 159–169 (2012).
pubmed: 22337149
doi: 10.1038/nrc3215
Di Sebastiano, K. M., Pinthus, J. H., Duivenvoorden, W. C. M. & Mourtzakis, M. Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise. Obes. Rev. 19, 1008–1016 (2018).
pubmed: 29573216
doi: 10.1111/obr.12674
Michalaki, V., Syrigos, K., Charles, P. & Waxman, J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer 90, 2312–2316 (2004).
pubmed: 15150588
pmcid: 2409519
doi: 10.1038/sj.bjc.6601814
Shariat, S. F. et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58, 1008–1015 (2001).
pubmed: 11744478
doi: 10.1016/S0090-4295(01)01405-4
Shariat, S. F. et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J. Clin. Oncol. 22, 1655–1663 (2004).
pubmed: 15117988
doi: 10.1200/JCO.2004.09.142
Uehara, H. et al. Adipose tissue: critical contributor to the development of prostate cancer. J. Med. Invest. 65, 9–17 (2018).
pubmed: 29593201
doi: 10.2152/jmi.65.9
Uehara, H., Takahashi, T., Oha, M., Ogawa, H. & Izumi, K. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int. J. Cancer 135, 2558–2568 (2014).
pubmed: 24740818
doi: 10.1002/ijc.28903
Laurent, V. et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat. Commun. 7, 10230 (2016).
pubmed: 26756352
pmcid: 4729927
doi: 10.1038/ncomms10230
Ferro, M. et al. The emerging role of obesity, diet and lipid metabolism in prostate cancer. Future Oncol. 13, 285–293 (2017).
pubmed: 27624840
doi: 10.2217/fon-2016-0217
Ito, Y. et al. Adipocyte-derived monocyte chemotactic protein-1 (MCP-1) promotes prostate cancer progression through the induction of MMP-2 activity. Prostate 75, 1009–1019 (2015).
pubmed: 25917126
doi: 10.1002/pros.22972
Xu, A. et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 52, 405–413 (2006).
pubmed: 16423904
doi: 10.1373/clinchem.2005.062463
Mohamed-Ali, V. et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82, 4196–4200 (1997).
pubmed: 9398739
Bastard, J. P. et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. 85, 3338–3342 (2000).
pubmed: 10999830
Roytblat, L. et al. Raised interleukin-6 levels in obese patients. Obes. Res. 8, 673–675 (2000).
pubmed: 11225716
doi: 10.1038/oby.2000.86
Rotter, V., Nagaev, I. & Smith, U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes andis, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 278, 45777–45784 (2003).
pubmed: 12952969
doi: 10.1074/jbc.M301977200
van Hall, G. et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J. Endocrinol. Metab. 88, 3005–3010 (2003).
doi: 10.1210/jc.2002-021687
Wedell-Neergaard, A. S. et al. Exercise-induced changes in visceral adipose tissue mass are regulated by IL-6 signaling: a randomized controlled trial. Cell Metab. 29, 844–855.e3 (2019).
pubmed: 30595477
doi: 10.1016/j.cmet.2018.12.007
Ikeda, S. I. et al. Exercise-induced increase in IL-6 level enhances GLUT4 expression and insulin sensitivity in mouse skeletal muscle. Biochem. Biophys. Res. Commun. 473, 947–952 (2016).
pubmed: 27040770
doi: 10.1016/j.bbrc.2016.03.159
Almendro, V. et al. Interleukin-15 increases calcineurin expression in 3T3-L1 cells: possible involvement on in vivo adipocyte differentiation. Int. J. Mol. Med. 24, 453–458 (2009).
pubmed: 19724884
Barra, N. G. et al. Interleukin-15 contributes to the regulation of murine adipose tissue and human adipocytes. Obesity 18, 1601–1607 (2010).
pubmed: 20019685
doi: 10.1038/oby.2009.445
Carbo, N. et al. Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim. Biophys. Acta. 1526, 17–24 (2001).
pubmed: 11287118
doi: 10.1016/S0304-4165(00)00188-4
Quinn, L. S., Anderson, B. G., Strait-Bodey, L., Stroud, A. M. & Argiles, J. M. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am. J. Physiol. Endocrinol. Metab. 296, E191–E202 (2009).
pubmed: 19001550
doi: 10.1152/ajpendo.90506.2008
Raschke, S., Eckardt, K., Bjorklund Holven, K., Jensen, J. & Eckel, J. Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cells. PLoS ONE 8, e62008 (2013).
pubmed: 23637948
pmcid: 3634789
doi: 10.1371/journal.pone.0062008
Nielsen, A. R. et al. Expression of interleukin-15 in human skeletal muscle effect of exercise and muscle fibre type composition. J. Physiol. 584, 305–312 (2007).
pubmed: 17690139
pmcid: 2277063
doi: 10.1113/jphysiol.2007.139618
Bazgir, B., Salesi, M., Koushki, M. & Amirghofran, Z. Effects of eccentric and concentric emphasized resistance exercise on IL-15 serum levels and its relation to inflammatory markers in athletes and non-athletes. Asian J. Sports Med. 6, e27980 (2015).
pubmed: 26448857
pmcid: 4594145
doi: 10.5812/asjsm.27980
Crane, J. D. et al. Exercise-stimulated interleukin-15 is controlled by AMPK and regulates skin metabolism and aging. Aging Cell 14, 625–634 (2015).
pubmed: 25902870
pmcid: 4531076
doi: 10.1111/acel.12341
Perez-Lopez, A. et al. Skeletal muscle IL-15/IL-15Ralpha and myofibrillar protein synthesis after resistance exercise. Scand. J. Med. Sci. Sports 28, 116–125 (2018).
pubmed: 28449327
doi: 10.1111/sms.12901
Riechman, S. E., Balasekaran, G., Roth, S. M. & Ferrell, R. E. Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses. J. Appl. Physiol. 97, 2214–2219 (2004).
pubmed: 15531573
doi: 10.1152/japplphysiol.00491.2004
Pierce, J. R., Maples, J. M. & Hickner, R. C. IL-15 concentrations in skeletal muscle and subcutaneous adipose tissue in lean and obese humans: local effects of IL-15 on adipose tissue lipolysis. Am. J. Physiol. Endocrinol. Metab. 308, E1131–E1139 (2015).
pubmed: 25921578
pmcid: 4469810
doi: 10.1152/ajpendo.00575.2014
Tamura, Y. et al. Upregulation of circulating IL-15 by treadmill running in healthy individuals: is IL-15 an endocrine mediator of the beneficial effects of endurance exercise? Endocr. J. 58, 211–215 (2011).
pubmed: 21307608
doi: 10.1507/endocrj.K10E-400
Noda, T. et al. Longterm exposure to leptin enhances the growth of prostate cancer cells. Int. J. Oncol. 46, 1535–1542 (2015).
pubmed: 25625287
doi: 10.3892/ijo.2015.2845
Busquets, S., Figueras, M., Almendro, V., Lopez-Soriano, F. J. & Argiles, J. M. Interleukin-15 increases glucose uptake in skeletal muscle. An antidiabetogenic effect of the cytokine. Biochim. Biophys. Acta. 1760, 1613–1617 (2006).
pubmed: 17056184
doi: 10.1016/j.bbagen.2006.09.001
Gray, S. R. & Kamolrat, T. The effect of exercise induced cytokines on insulin stimulated glucose transport in C2C12 cells. Cytokine 55, 221–228 (2011).
pubmed: 21600784
doi: 10.1016/j.cyto.2011.04.019
Krolopp, J. E., Thornton, S. M. & Abbott, M. J. IL-15 activates the Jak3/STAT3 signaling pathway to mediate glucose uptake in skeletal muscle cells. Front. Physiol. 7, 626 (2016).
pubmed: 28066259
pmcid: 5167732
doi: 10.3389/fphys.2016.00626
Quinn, L. S., Anderson, B. G., Conner, J. D. & Wolden-Hanson, T. IL-15 overexpression promotes endurance, oxidative energy metabolism, and muscle PPARdelta, SIRT1, PGC-1alpha, and PGC-1beta expression in male mice. Endocrinology 154, 232–245 (2013).
pubmed: 23161867
doi: 10.1210/en.2012-1773
Ferrannini, E. et al. Effect of insulin on the distribution and disposition of glucose in man. J. Clin. Invest. 76, 357–364 (1985).
pubmed: 3894421
pmcid: 423783
doi: 10.1172/JCI111969
Schnyder, S. & Handschin, C. Skeletal muscle as an endocrine organ: PGC-1alpha, myokines and exercise. Bone 80, 115–125 (2015).
pubmed: 26453501
pmcid: 4657151
doi: 10.1016/j.bone.2015.02.008
Marshall, A. et al. Mighty is a novel promyogenic factor in skeletal myogenesis. Exp. Cell Res. 314, 1013–1029 (2008).
pubmed: 18255059
doi: 10.1016/j.yexcr.2008.01.004
Zhu, J. et al. Relationships between transforming growth factor-beta1, myostatin, and decorin: implications for skeletal muscle fibrosis. J. Biol. Chem. 282, 25852–25863 (2007).
pubmed: 17597062
doi: 10.1074/jbc.M704146200
Hittel, D. S. et al. Myostatin decreases with aerobic exercise and associates with insulin resistance. Med. Sci. Sports Exerc. 42, 2023–2029 (2010).
pubmed: 20386333
pmcid: 2975387
doi: 10.1249/MSS.0b013e3181e0b9a8
Konopka, A. R. et al. Molecular adaptations to aerobic exercise training in skeletal muscle of older women. J. Gerontol. A Biol. Sci. Med. Sci. 65, 1201–1207 (2010).
pubmed: 20566734
doi: 10.1093/gerona/glq109
Kopple, J. D. et al. Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients. J. Ren. Nutr. 16, 312–324 (2006).
pubmed: 17046615
doi: 10.1053/j.jrn.2006.04.028
Laurentino, G. C. et al. Strength training with blood flow restriction diminishes myostatin gene expression. Med. Sci. Sports Exerc. 44, 406–412 (2012).
pubmed: 21900845
doi: 10.1249/MSS.0b013e318233b4bc
Louis, E., Raue, U., Yang, Y., Jemiolo, B. & Trappe, S. Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle. J. Appl. Physiol. 103, 1744–1751 (2007).
pubmed: 17823296
doi: 10.1152/japplphysiol.00679.2007
Mascher, H. et al. Repeated resistance exercise training induces different changes in mRNA expression of MAFbx and MuRF-1 in human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 294, E43–E51 (2008).
pubmed: 17971512
doi: 10.1152/ajpendo.00504.2007
Matsakas, A., Friedel, A., Hertrampf, T. & Diel, P. Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat. Acta. Physiol. Scand. 183, 299–307 (2005).
pubmed: 15743390
doi: 10.1111/j.1365-201X.2005.01406.x
Roth, S. M. et al. Myostatin gene expression is reduced in humans with heavy-resistance strength training: a brief communication. Exp. Biol. Med. 228, 706–709 (2003).
doi: 10.1177/153537020322800609
Seyedi, S. H. & Ramezanpour, M. R. The effect of a single bout of resistance exercise on serum level of myostatin and follistatin in elderly men. Cibtech J. Zool. 4, 19–26 (2015).
White, T. A. & LeBrasseur, N. K. Myostatin and sarcopenia: opportunities and challenges — a mini-review. Gerontology 60, 289–293 (2014).
pubmed: 24457615
doi: 10.1159/000356740
McPherron, A. C. & Lee, S. J. Suppression of body fat accumulation in myostatin-deficient mice. J. Clin. Invest. 109, 595–601 (2002).
pubmed: 11877467
pmcid: 150888
doi: 10.1172/JCI0213562
Zhang, C. et al. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia 55, 183–193 (2012).
pubmed: 21927895
doi: 10.1007/s00125-011-2304-4
Dong, J. et al. Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues. Int. J. Obes. 40, 434–442 (2016).
doi: 10.1038/ijo.2015.200
Shan, T., Liang, X., Bi, P. & Kuang, S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1alpha-Fndc5 pathway in muscle. FASEB J. 27, 1981–1989 (2013).
pubmed: 23362117
pmcid: 3633817
doi: 10.1096/fj.12-225755
Akpan, I. et al. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int. J. Obes. 33, 1265–1273 (2009).
doi: 10.1038/ijo.2009.162
Bernardo, B. L. et al. Postnatal PPARdelta activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice. PLoS ONE 5, e11307 (2010).
pubmed: 20593012
pmcid: 2892469
doi: 10.1371/journal.pone.0011307
Freedland, S. J., Williams, C. D. & Masko, E. M. Adiponectin and prostate cancer mortality: to be or not to be skinny? Clin. Chem. 56, 1–3 (2010).
pubmed: 19892841
doi: 10.1373/clinchem.2009.137406
Mistry, T., Digby, J. E., Desai, K. M. & Randeva, H. S. Obesity and prostate cancer: a role for adipokines. Eur. Urol. 52, 46–53 (2007).
pubmed: 17399889
doi: 10.1016/j.eururo.2007.03.054
Reddy, N. L., Tan, B. K., Barber, T. M. & Randeva, H. S. Brown adipose tissue: endocrine determinants of function and therapeutic manipulation as a novel treatment strategy for obesity. BMC Obes. 1, 13 (2014).
pubmed: 26937283
pmcid: 4765227
doi: 10.1186/s40608-014-0013-5
Arhire, L. I., Mihalache, L. & Covasa, M. Irisin: a hope in understanding and managing obesity and metabolic syndrome. Front. Endocrinol. 10, 524 (2019).
doi: 10.3389/fendo.2019.00524
Zhang, Y. et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 63, 514–525 (2014).
pubmed: 24150604
doi: 10.2337/db13-1106
Mazur-Bialy, A. I., Bilski, J., Pochec, E. & Brzozowski, T. New insight into the direct anti-inflammatory activity of a myokine irisin against proinflammatory activation of adipocytes. Implication for exercise in obesity. J. Physiol. Pharmacol. 68, 243–251 (2017).
pubmed: 28614774
Kamei, N. et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem. 281, 26602–26614 (2006).
pubmed: 16809344
doi: 10.1074/jbc.M601284200
Kanda, H. et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116, 1494–1505 (2006).
pubmed: 16691291
pmcid: 1459069
doi: 10.1172/JCI26498
Spiegelman, B. M. & Ginty, C. A. Fibronectin modulation of cell shape and lipogenic gene expression in 3T3-adipocytes. Cell 35, 657–666 (1983).
pubmed: 6686086
doi: 10.1016/0092-8674(83)90098-3
Liu, J. et al. Changes in integrin expression during adipocyte differentiation. Cell Metab. 2, 165–177 (2005).
pubmed: 16154099
doi: 10.1016/j.cmet.2005.08.006
Nagaraju, G. P. & Sharma, D. Anti-cancer role of SPARC, an inhibitor of adipogenesis. Cancer Treat. Rev. 37, 559–566 (2011).
pubmed: 21237573
pmcid: 3139810
doi: 10.1016/j.ctrv.2010.12.001
Bradshaw, A. D., Graves, D. C., Motamed, K. & Sage, E. H. SPARC-null mice exhibit increased adiposity without significant differences in overall body weight. Proc. Natl Acad. Sci. USA 100, 6045–6050 (2003).
pubmed: 12721366
pmcid: 156323
doi: 10.1073/pnas.1030790100
Kang, S. et al. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 282, 14515–14524 (2007).
pubmed: 17351296
doi: 10.1074/jbc.M700030200
Laukkanen, J. A. et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol. Biomarkers Prev. 13, 1646–1650 (2004).
pubmed: 15466982
doi: 10.1158/1055-9965.1646.13.10
Gacci, M. et al. Meta-analysis of metabolic syndrome and prostate cancer. Prostate Cancer Prostatic Dis. 20, 146–155 (2017).
pubmed: 28220805
doi: 10.1038/pcan.2017.1
Saylor, P. J. & Smith, M. R. Metabolic complications of androgen deprivation therapy for prostate cancer. J. Urol. 189, S34–S42; discussion S43–44 (2013).
pubmed: 23234628
doi: 10.1016/j.juro.2012.11.017
Caliskan, S. et al. The effect of metabolic syndrome on prostate cancer final pathology. J. Cancer Res. Ther. 15, S47–S50 (2019).
pubmed: 30900620
doi: 10.4103/0973-1482.187290
Yu, Y. R. & Ho, P. C. Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting. Clin. Exp. Immunol. 197, 153–160 (2019).
pubmed: 30873592
doi: 10.1111/cei.13293
Engelhardt, J. J. et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21, 402–417 (2012).
pubmed: 22439936
pmcid: 3311997
doi: 10.1016/j.ccr.2012.01.008
Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162–174 (2009).
pubmed: 19197294
pmcid: 2828349
doi: 10.1038/nri2506
Gallina, G. et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8
pubmed: 17016559
pmcid: 1578632
doi: 10.1172/JCI28828
Kuang, D. M. et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206, 1327–1337 (2009).
pubmed: 19451266
pmcid: 2715058
doi: 10.1084/jem.20082173
Kusmartsev, S., Nagaraj, S. & Gabrilovich, D. I. Tumor-associated CD8
pubmed: 16177103
doi: 10.4049/jimmunol.175.7.4583
Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).
pubmed: 25858804
pmcid: 4400238
doi: 10.1016/j.ccell.2015.03.001
Cascone, T. et al. Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab. 27, 977–987 (2018).
pubmed: 29628419
pmcid: 5932208
doi: 10.1016/j.cmet.2018.02.024
Ho, P. C. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217–1228 (2015).
pubmed: 26321681
pmcid: 4567953
doi: 10.1016/j.cell.2015.08.012
Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229–1241 (2015).
pubmed: 26321679
pmcid: 4864363
doi: 10.1016/j.cell.2015.08.016
Doedens, A. L. et al. Hypoxia-inducible factors enhance the effector responses of CD8
pubmed: 24076634
pmcid: 3977965
doi: 10.1038/ni.2714
Kruijsen-Jaarsma, M., Revesz, D., Bierings, M. B., Buffart, L. M. & Takken, T. Effects of exercise on immune function in patients with cancer: a systematic review. Exer. Immunol. Rev. 19, 120–143 (2013).
Shephard, R. J. & Shek, P. N. Effects of exercise and training on natural killer cell counts and cytolytic activity: a meta-analysis. Sports Med. 28, 177–195 (1999).
pubmed: 10541441
doi: 10.2165/00007256-199928030-00003
Timmons, B. W. & Cieslak, T. Human natural killer cell subsets and acute exercise: a brief review. Exerc. Immunol. Rev. 14, 8–23 (2008).
pubmed: 19203081
Pedersen, L. et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 23, 554–562 (2016).
pubmed: 26895752
doi: 10.1016/j.cmet.2016.01.011
Clahsen, T. & Schaper, F. Interleukin-6 acts in the fashion of a classical chemokine on monocytic cells by inducing integrin activation, cell adhesion, actin polymerization, chemotaxis, and transmigration. J. Leukoc. Biol. 84, 1521–1529 (2008).
pubmed: 18765478
doi: 10.1189/jlb.0308178
Fisher, D. T. et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J. Clin. Invest. 121, 3846–3859 (2011).
pubmed: 21926464
pmcid: 3195455
doi: 10.1172/JCI44952
Idorn, M. & Hojman, P. Exercise-dependent regulation of NK cells in cancer protection. Trends Mol. Med. 22, 565–577 (2016).
pubmed: 27262760
doi: 10.1016/j.molmed.2016.05.007
Kaplanski, G., Marin, V., Montero-Julian, F., Mantovani, A. & Farnarier, C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 24, 25–29 (2003).
pubmed: 12495721
doi: 10.1016/S1471-4906(02)00013-3
Madden, K. S. & Felten, D. L. Experimental basis for neural-immune interactions. Physiol. Rev. 75, 77–106 (1995).
pubmed: 7831399
doi: 10.1152/physrev.1995.75.1.77
Nagao, F., Suzui, M., Takeda, K., Yagita, H. & Okumura, K. Mobilization of NK cells by exercise: downmodulation of adhesion molecules on NK cells by catecholamines. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1251–R1256 (2000).
pubmed: 11003990
doi: 10.1152/ajpregu.2000.279.4.R1251
Robinson, T. O. & Schluns, K. S. The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol. Lett. 190, 159–168 (2017).
pubmed: 28823521
pmcid: 5774016
doi: 10.1016/j.imlet.2017.08.010
Kennedy, M. K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771–780 (2000).
pubmed: 10704459
pmcid: 2195858
doi: 10.1084/jem.191.5.771
Lodolce, J. P. et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9, 669–676 (1998).
pubmed: 9846488
doi: 10.1016/S1074-7613(00)80664-0
Tang, F. et al. Activity of recombinant human interleukin-15 against tumor recurrence and metastasis in mice. Cell Mol. Immunol. 5, 189–196 (2008).
pubmed: 18582400
pmcid: 4651289
doi: 10.1038/cmi.2008.23
Morris, J. C. et al. Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer. Gene. Ther. 21, 393–401 (2014).
pubmed: 24572789
pmcid: 3976433
doi: 10.1038/gt.2014.10
Cabral-Santos, C. et al. Inflammatory cytokines and BDNF response to high-intensity intermittent exercise: effect the exercise volume. Front. Physiol. 7, 509 (2016).
pubmed: 27867360
pmcid: 5095487
doi: 10.3389/fphys.2016.00509
Chupel, M. U. et al. Strength training decreases inflammation and increases cognition and physical fitness in older women with cognitive impairment. Front. Physiol. 8, 377 (2017).
pubmed: 28659812
pmcid: 5467003
doi: 10.3389/fphys.2017.00377
Dorneles, G. P. et al. High intensity interval exercise decreases IL-8 and enhances the immunomodulatory cytokine interleukin-10 in lean and overweight-obese individuals. Cytokine 77, 1–9 (2016).
pubmed: 26476404
doi: 10.1016/j.cyto.2015.10.003
Ghafourian, M., Ashtary-Larky, D., Chinipardaz, R., Eskandary, N. & Mehavaran, M. Inflammatory biomarkers’ response to two different intensities of a single bout exercise among soccer players. Iran. Red. Crescent Med. J. 18, e21498 (2016).
pubmed: 27175304
pmcid: 4862257
Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A. & Hymowitz, S. G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29, 71–109 (2011).
pubmed: 21166540
doi: 10.1146/annurev-immunol-031210-101312
Mannino, M. H. et al. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 367, 103–107 (2015).
pubmed: 26188281
doi: 10.1016/j.canlet.2015.07.009
Fiorentino, D. F., Bond, M. W. & Mosmann, T. R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170, 2081–2095 (1989).
pubmed: 2531194
doi: 10.1084/jem.170.6.2081
Groux, H., Bigler, M., de Vries, J. E. & Roncarolo, M. G. Inhibitory and stimulatory effects of IL-10 on human CD8
pubmed: 9531274
doi: 10.4049/jimmunol.160.7.3188
MacNeil, I. A., Suda, T., Moore, K. W., Mosmann, T. R. & Zlotnik, A. IL-10, a novel growth cofactor for mature and immature T cells. J. Immunol. 145, 4167–4173 (1990).
pubmed: 2124236
doi: 10.4049/jimmunol.145.12.4167
Moore, K. W., de Waal Malefyt, R., Coffman, R. L. & O’Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683–765 (2001).
pubmed: 11244051
doi: 10.1146/annurev.immunol.19.1.683
Groux, H. et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J. Immunol. 162, 1723–1729 (1999).
pubmed: 9973435
doi: 10.4049/jimmunol.162.3.1723
Berman, R. M. et al. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J. Immunol. 157, 231–238 (1996).
pubmed: 8683120
doi: 10.4049/jimmunol.157.1.231
Fujii, S., Shimizu, K., Shimizu, T. & Lotze, M. T. Interleukin-10 promotes the maintenance of antitumor CD8
pubmed: 11568001
doi: 10.1182/blood.V98.7.2143
Smith, M. R. et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 87, 599–603 (2002).
pubmed: 11836291
doi: 10.1210/jcem.87.2.8299
Schmitz, K. H. et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. CA Cancer J. Clin. 69, 468–484 (2019).
pubmed: 31617590
pmcid: 7896280
doi: 10.3322/caac.21579
Hojan, K. et al. Physical exercise for functional capacity, blood immune function, fatigue, and quality of life in high-risk prostate cancer patients during radiotherapy: a prospective, randomized clinical study. Eur. J. Phys. Rehabil. Med. 52, 489–501 (2016).
pubmed: 26761561
Park, J. et al. Effects of progressive resistance training on post-surgery incontinence in men with prostate cancer. J. Clin. Med. 7, 292 (2018).
pmcid: 6162607
doi: 10.3390/jcm7090292
Newton, R. U. et al. Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open 8, e022899 (2018).
pubmed: 29764892
pmcid: 5961562
doi: 10.1136/bmjopen-2018-022899
Campbell, K. L. et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med. Sci. Sports Exerc. 51, 2375–2390 (2019).
pubmed: 31626055
doi: 10.1249/MSS.0000000000002116
pmcid: 8576825
Ajuwon, K. M. & Spurlock, M. E. Direct regulation of lipolysis by interleukin-15 in primary pig adipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287, R608–R611 (2004).
pubmed: 15155279
doi: 10.1152/ajpregu.00192.2004
Gao, S. et al. Effects and molecular mechanism of GST-irisin on lipolysis and autocrine function in 3T3-L1 adipocytes. PLoS ONE 11, e0147480 (2016).
pubmed: 26799325
pmcid: 4723061
doi: 10.1371/journal.pone.0147480